112 related articles for article (PubMed ID: 22480520)
1. The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis.
Cianfrocca R; Tocci P; Spinella F; Di Castro V; Bagnato A; Rosanò L
Life Sci; 2012 Oct; 91(13-14):550-6. PubMed ID: 22480520
[TBL] [Abstract][Full Text] [Related]
2. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
Rosanò L; Di Castro V; Spinella F; Tortora G; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2007 Jul; 67(13):6351-9. PubMed ID: 17616694
[TBL] [Abstract][Full Text] [Related]
3. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
Spinella F; Rosanò L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
[TBL] [Abstract][Full Text] [Related]
5. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells.
Rosanò L; Spinella F; Di Castro V; Nicotra MR; Dedhar S; de Herreros AG; Natali PG; Bagnato A
Cancer Res; 2005 Dec; 65(24):11649-57. PubMed ID: 16357176
[TBL] [Abstract][Full Text] [Related]
6. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis.
Rosanò L; Cianfrocca R; Masi S; Spinella F; Di Castro V; Biroccio A; Salvati E; Nicotra MR; Natali PG; Bagnato A
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2806-11. PubMed ID: 19202075
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.
Bagnato A; Rosanò L
Cells Tissues Organs; 2007; 185(1-3):85-94. PubMed ID: 17587812
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
[TBL] [Abstract][Full Text] [Related]
9. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
Knowlden JM; Jones HE; Barrow D; Gee JM; Nicholson RI; Hutcheson IR
Breast Cancer Res Treat; 2008 Sep; 111(1):79-91. PubMed ID: 17902048
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
[TBL] [Abstract][Full Text] [Related]
11. Expression and tyrosine phosphorylation of E-cadherin, beta- and gamma-catenin, and epidermal growth factor receptor in cervical cancer cells.
Moon HS; Choi EA; Park HY; Choi JY; Chung HW; Kim JI; Park WI
Gynecol Oncol; 2001 Jun; 81(3):355-9. PubMed ID: 11371122
[TBL] [Abstract][Full Text] [Related]
12. β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling.
Rosanò L; Cianfrocca R; Tocci P; Spinella F; Di Castro V; Spadaro F; Salvati E; Biroccio AM; Natali PG; Bagnato A
Oncogene; 2013 Oct; 32(42):5066-77. PubMed ID: 23208497
[TBL] [Abstract][Full Text] [Related]
13. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
14. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor/beta-catenin/T-cell factor 4/matrix metalloproteinase 1: a new pathway for regulating keratinocyte invasiveness after UVA irradiation.
Jean C; Blanc A; Prade-Houdellier N; Ysebaert L; Hernandez-Pigeon H; Al Saati T; Haure MJ; Coluccia AM; Charveron M; Delabesse E; Laurent G
Cancer Res; 2009 Apr; 69(8):3291-9. PubMed ID: 19336574
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors.
Pai R; Nakamura T; Moon WS; Tarnawski AS
FASEB J; 2003 Sep; 17(12):1640-7. PubMed ID: 12958170
[TBL] [Abstract][Full Text] [Related]
18. Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells.
Park JJ; Yi JY; Jin YB; Lee YJ; Lee JS; Lee YS; Ko YG; Lee M
Biochem Pharmacol; 2012 Apr; 83(7):849-57. PubMed ID: 22266356
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
[TBL] [Abstract][Full Text] [Related]
20. Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression.
Rosanò L; Spinella F; Di Castro V; Decandia S; Nicotra MR; Natali PG; Bagnato A
Exp Biol Med (Maywood); 2006 Jun; 231(6):1128-31. PubMed ID: 16741062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
